Crispr Therapeutics shares tumble after significant earnings miss
Investing.com -- The Brink’s Company (NYSE:BCO), a global provider of cash and valuables management services, reported first-quarter earnings that surpassed analyst expectations, but its shares slipped 1.5% as the company’s second-quarter guidance fell short of estimates.
Brink’s posted adjusted earnings per share of $1.62 for the first quarter, beating the analyst consensus of $1.37. Revenue came in at $1.25 billion, slightly above the expected $1.21 billion and representing a 1% increase YoY. Organic revenue growth was 6%, driven by strong performance in ATM managed services and digital retail solutions, which grew over 20%.
Despite the earnings beat, investors appeared concerned about the company’s outlook. Brink’s provided second-quarter EPS guidance of $1.25-$1.65, with the midpoint falling below the consensus estimate of $1.62. The company expects Q2 revenue between $1.25-1.3 billion, roughly in line with analyst expectations.
Mark Eubanks, president and CEO of Brink’s, commented on the results: "We delivered strong performance in the first quarter with EBITDA and EPS exceeding the top end of our guidance range. Organic revenue growth of 6% included 20% growth in AMS (VIE:AMS2) and DRS."
The company’s operating profit margin improved by 40 basis points on a non-GAAP basis, reflecting productivity gains and revenue mix benefits, partially offset by currency headwinds, particularly in Latin America.
Brink’s reaffirmed its 2025 framework, which includes mid-single-digit organic revenue growth and adjusted EBITDA margin expansion of 30-50 basis points. The company also highlighted its ongoing share repurchase program, having bought back over 1.3 million shares year-to-date.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.